Related references
Note: Only part of the references are listed.Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Suetonia C. Palmer et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? Completed and Ongoing Mechanistic Trials
Matthew M. Y. Lee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2020)
Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
Olivia R Ghosh-Swaby et al.
Lancet Diabetes & Endocrinology (2020)
Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials
Edoardo Mannucci et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)
Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study
Antonio Ceriello et al.
DIABETES CARE (2019)
Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
B. M. Bonora et al.
ACTA DIABETOLOGICA (2019)
Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis
D. Giugliano et al.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION (2019)
Class effects of SGLT2 inhibitors on cardiorenal outcomes
Aaron Y. Kluger et al.
CARDIOVASCULAR DIABETOLOGY (2019)
The elephant in the room: Why cardiologists should stop ignoring type 2 diabetes
James H. O'Keefe et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2019)
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies
Kausik K. Ray et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study
Daniel I. Bromage et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017
Thomas R. Einarson et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes A Systematic Review and Meta-analysis
Sean L. Zheng et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study
Araz Rawshani et al.
LANCET (2018)
Diabetes and Prior Coronary Heart Disease are Not Necessarily Risk Equivalent for Future Coronary Heart Disease Events
Jamal S. Rana et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2016)
Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study
Edward W. Gregg et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis
Caroline K. Kramer et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Quality of Diabetes Care Predicts the Development of Cardiovascular Events: Results of the AMD-QUASAR Study
Maria C. E. Rossi et al.
DIABETES CARE (2011)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Is diabetes a coronary risk equivalent? Systematic review and meta-analysis
U. Bulugahapitiya et al.
DIABETIC MEDICINE (2009)
Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics
Maria C. E. Rossi et al.
DIABETES CARE (2008)
Quality of diabetes care predicts the development of cardiovascular events: Results of the QuED study
Giorgia De Berardis et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2008)
Prognostic value of coronary artery calcium screening in subjects with and without diabetes
P Raggi et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2004)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
